Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Aortic Valve | 13 | 2018 | 49 | 2.180 |
Why?
|
Bioprosthesis | 10 | 2018 | 58 | 1.660 |
Why?
|
Cardiac Surgical Procedures | 10 | 2021 | 73 | 1.460 |
Why?
|
Heart Valve Prosthesis Implantation | 8 | 2018 | 39 | 1.360 |
Why?
|
Heart Valve Prosthesis | 9 | 2018 | 55 | 1.270 |
Why?
|
Cardiopulmonary Bypass | 9 | 2012 | 56 | 1.030 |
Why?
|
Coronary Artery Bypass | 9 | 2013 | 103 | 1.020 |
Why?
|
Pulmonary Artery | 3 | 2012 | 24 | 0.710 |
Why?
|
Heart Valve Diseases | 6 | 2020 | 27 | 0.700 |
Why?
|
Myocardial Ischemia | 4 | 2020 | 107 | 0.640 |
Why?
|
Prosthesis Design | 6 | 2018 | 97 | 0.600 |
Why?
|
Mitral Valve Insufficiency | 2 | 2011 | 25 | 0.600 |
Why?
|
Esophagus | 2 | 2015 | 22 | 0.580 |
Why?
|
Coronary Disease | 3 | 2007 | 211 | 0.570 |
Why?
|
Chymases | 4 | 2020 | 8 | 0.570 |
Why?
|
Aortic Valve Insufficiency | 7 | 2018 | 24 | 0.560 |
Why?
|
Congenital Abnormalities | 1 | 2015 | 9 | 0.530 |
Why?
|
Larynx | 1 | 2015 | 20 | 0.520 |
Why?
|
Abnormalities, Multiple | 1 | 2015 | 28 | 0.520 |
Why?
|
Trachea | 1 | 2015 | 52 | 0.510 |
Why?
|
Postoperative Complications | 7 | 2013 | 780 | 0.490 |
Why?
|
Coronary Vessel Anomalies | 2 | 2012 | 6 | 0.490 |
Why?
|
Aortic Valve Stenosis | 5 | 2020 | 30 | 0.480 |
Why?
|
Echocardiography, Transesophageal | 6 | 2012 | 42 | 0.470 |
Why?
|
Blood Loss, Surgical | 2 | 2011 | 49 | 0.460 |
Why?
|
Aged | 27 | 2021 | 10301 | 0.450 |
Why?
|
Extracellular Matrix | 1 | 2015 | 245 | 0.450 |
Why?
|
Cognition Disorders | 2 | 2007 | 385 | 0.440 |
Why?
|
Humans | 45 | 2021 | 32005 | 0.440 |
Why?
|
Aortic Aneurysm | 2 | 2010 | 11 | 0.430 |
Why?
|
Female | 32 | 2020 | 19959 | 0.420 |
Why?
|
Antifibrinolytic Agents | 2 | 2013 | 16 | 0.410 |
Why?
|
Middle Aged | 25 | 2020 | 11817 | 0.410 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 3 | 2017 | 135 | 0.410 |
Why?
|
Male | 33 | 2020 | 19165 | 0.400 |
Why?
|
Embolism, Cholesterol | 1 | 2011 | 6 | 0.380 |
Why?
|
Sinus of Valsalva | 1 | 2010 | 2 | 0.370 |
Why?
|
Angiotensinogen | 4 | 2020 | 59 | 0.370 |
Why?
|
Mitral Valve | 3 | 2011 | 32 | 0.370 |
Why?
|
Ventricular Function, Left | 2 | 2020 | 245 | 0.370 |
Why?
|
Aortic Aneurysm, Thoracic | 2 | 2015 | 11 | 0.360 |
Why?
|
Coronary Artery Bypass, Off-Pump | 2 | 2007 | 6 | 0.340 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2011 | 510 | 0.330 |
Why?
|
Angiotensin II | 3 | 2015 | 244 | 0.320 |
Why?
|
Follow-Up Studies | 10 | 2020 | 2265 | 0.320 |
Why?
|
Heart Diseases | 2 | 2010 | 116 | 0.320 |
Why?
|
Aprotinin | 2 | 2005 | 4 | 0.320 |
Why?
|
Aorta, Thoracic | 2 | 2006 | 85 | 0.320 |
Why?
|
Heart Valves | 2 | 2005 | 16 | 0.300 |
Why?
|
Reoperation | 6 | 2011 | 226 | 0.300 |
Why?
|
Treatment Outcome | 15 | 2018 | 3306 | 0.290 |
Why?
|
Heart Atria | 2 | 2020 | 65 | 0.290 |
Why?
|
Aneurysm, Dissecting | 2 | 2004 | 12 | 0.290 |
Why?
|
Risk Factors | 9 | 2018 | 3876 | 0.260 |
Why?
|
Serine Proteinase Inhibitors | 1 | 2005 | 6 | 0.260 |
Why?
|
Peptide Fragments | 2 | 2020 | 399 | 0.260 |
Why?
|
Adult | 16 | 2020 | 9345 | 0.260 |
Why?
|
Echocardiography | 4 | 2020 | 159 | 0.250 |
Why?
|
Time Factors | 7 | 2018 | 2149 | 0.240 |
Why?
|
Retrospective Studies | 8 | 2018 | 3509 | 0.240 |
Why?
|
Aneurysm, False | 2 | 2015 | 14 | 0.220 |
Why?
|
Aged, 80 and over | 7 | 2018 | 3990 | 0.210 |
Why?
|
Equipment Failure Analysis | 1 | 2002 | 42 | 0.210 |
Why?
|
Atrial Fibrillation | 3 | 2020 | 322 | 0.210 |
Why?
|
Vascular Surgical Procedures | 2 | 2017 | 88 | 0.190 |
Why?
|
Atrial Appendage | 1 | 2021 | 10 | 0.190 |
Why?
|
Infant, Newborn | 2 | 2015 | 671 | 0.190 |
Why?
|
Postoperative Hemorrhage | 3 | 2013 | 42 | 0.180 |
Why?
|
Cardiac-Gated Imaging Techniques | 2 | 2012 | 18 | 0.180 |
Why?
|
Endocarditis | 2 | 2012 | 15 | 0.180 |
Why?
|
Infant | 2 | 2015 | 1061 | 0.170 |
Why?
|
Prosthesis Failure | 2 | 2018 | 45 | 0.170 |
Why?
|
Blood Vessel Prosthesis Implantation | 3 | 2012 | 69 | 0.170 |
Why?
|
Atherosclerosis | 1 | 2006 | 766 | 0.170 |
Why?
|
Severity of Illness Index | 5 | 2020 | 881 | 0.170 |
Why?
|
Animals | 9 | 2020 | 7541 | 0.160 |
Why?
|
Tomography, X-Ray Computed | 4 | 2012 | 918 | 0.160 |
Why?
|
Stents | 2 | 2018 | 177 | 0.160 |
Why?
|
Hypertension | 2 | 2017 | 959 | 0.160 |
Why?
|
Catheterization, Peripheral | 1 | 2017 | 29 | 0.150 |
Why?
|
Femoral Artery | 1 | 2017 | 50 | 0.150 |
Why?
|
Aorta | 2 | 2011 | 126 | 0.140 |
Why?
|
Swine | 3 | 2009 | 215 | 0.140 |
Why?
|
Tracheotomy | 1 | 2015 | 1 | 0.130 |
Why?
|
Renin-Angiotensin System | 1 | 2017 | 179 | 0.130 |
Why?
|
Hemodynamics | 4 | 2018 | 155 | 0.120 |
Why?
|
Hospital Mortality | 3 | 2006 | 198 | 0.120 |
Why?
|
Stroke | 1 | 2020 | 585 | 0.120 |
Why?
|
Factor IX | 1 | 2013 | 11 | 0.110 |
Why?
|
Angiotensin I | 1 | 2015 | 241 | 0.110 |
Why?
|
Preoperative Care | 3 | 2012 | 114 | 0.110 |
Why?
|
Age Factors | 2 | 2007 | 1188 | 0.110 |
Why?
|
Prognosis | 4 | 2020 | 1497 | 0.110 |
Why?
|
Mitral Valve Stenosis | 1 | 2012 | 8 | 0.110 |
Why?
|
Length of Stay | 3 | 2017 | 314 | 0.110 |
Why?
|
Echocardiography, Doppler | 2 | 2010 | 45 | 0.100 |
Why?
|
Probability | 3 | 2007 | 158 | 0.100 |
Why?
|
Coronary Angiography | 1 | 2012 | 153 | 0.100 |
Why?
|
Dexmedetomidine | 1 | 2011 | 8 | 0.100 |
Why?
|
Hypnotics and Sedatives | 1 | 2011 | 28 | 0.100 |
Why?
|
Propofol | 1 | 2011 | 19 | 0.100 |
Why?
|
Heart Aneurysm | 1 | 2011 | 3 | 0.100 |
Why?
|
Survival Rate | 3 | 2010 | 877 | 0.090 |
Why?
|
Heart Failure | 1 | 2017 | 639 | 0.090 |
Why?
|
Transplantation, Homologous | 1 | 2010 | 151 | 0.090 |
Why?
|
Cerebrovascular Circulation | 1 | 2011 | 93 | 0.090 |
Why?
|
Elasticity Imaging Techniques | 1 | 2010 | 12 | 0.090 |
Why?
|
Bioreactors | 1 | 2009 | 60 | 0.080 |
Why?
|
Constriction | 2 | 2005 | 12 | 0.080 |
Why?
|
Intraoperative Care | 2 | 2012 | 48 | 0.080 |
Why?
|
Ticlopidine | 1 | 2008 | 17 | 0.080 |
Why?
|
Premedication | 1 | 2008 | 13 | 0.080 |
Why?
|
Ventricular Remodeling | 2 | 2020 | 58 | 0.080 |
Why?
|
Endothelial Cells | 1 | 2009 | 189 | 0.080 |
Why?
|
Surgical Instruments | 1 | 2007 | 24 | 0.070 |
Why?
|
Survival Analysis | 3 | 2020 | 483 | 0.070 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2008 | 83 | 0.070 |
Why?
|
Saphenous Vein | 1 | 2007 | 20 | 0.070 |
Why?
|
Cardiac Pacing, Artificial | 1 | 2007 | 9 | 0.070 |
Why?
|
Child, Preschool | 1 | 2011 | 1269 | 0.070 |
Why?
|
Sex Distribution | 1 | 2007 | 191 | 0.070 |
Why?
|
Postoperative Care | 1 | 2007 | 76 | 0.070 |
Why?
|
Neuropsychological Tests | 1 | 2007 | 371 | 0.070 |
Why?
|
RNA, Messenger | 2 | 2020 | 508 | 0.070 |
Why?
|
Prospective Studies | 3 | 2008 | 2282 | 0.070 |
Why?
|
Logistic Models | 2 | 2005 | 781 | 0.070 |
Why?
|
Hematocrit | 1 | 2005 | 23 | 0.070 |
Why?
|
Postoperative Period | 1 | 2006 | 97 | 0.070 |
Why?
|
Causality | 1 | 2005 | 38 | 0.070 |
Why?
|
Drug Interactions | 1 | 2005 | 78 | 0.060 |
Why?
|
Nervous System Diseases | 1 | 2005 | 39 | 0.060 |
Why?
|
Hyperglycemia | 1 | 2005 | 84 | 0.060 |
Why?
|
North Carolina | 2 | 2010 | 1514 | 0.060 |
Why?
|
Drug Therapy, Combination | 1 | 2005 | 288 | 0.060 |
Why?
|
Heart Rate | 1 | 2007 | 335 | 0.060 |
Why?
|
Mental Disorders | 1 | 2005 | 121 | 0.060 |
Why?
|
Cattle | 1 | 2004 | 103 | 0.060 |
Why?
|
Polyethylene Terephthalates | 1 | 2004 | 3 | 0.060 |
Why?
|
Pericardium | 1 | 2004 | 52 | 0.060 |
Why?
|
Insulin | 2 | 2005 | 367 | 0.060 |
Why?
|
Multivariate Analysis | 1 | 2005 | 684 | 0.060 |
Why?
|
Comorbidity | 1 | 2005 | 566 | 0.060 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2003 | 6 | 0.060 |
Why?
|
Suture Techniques | 1 | 2004 | 61 | 0.060 |
Why?
|
Body Mass Index | 1 | 2007 | 923 | 0.060 |
Why?
|
Enoxaparin | 1 | 2003 | 20 | 0.060 |
Why?
|
Hemoglobins | 1 | 2003 | 49 | 0.060 |
Why?
|
Heart Arrest, Induced | 1 | 2003 | 3 | 0.060 |
Why?
|
Hemostatics | 1 | 2003 | 11 | 0.060 |
Why?
|
Hypothermia, Induced | 1 | 2003 | 17 | 0.060 |
Why?
|
Tissue Engineering | 1 | 2009 | 656 | 0.050 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2004 | 170 | 0.050 |
Why?
|
Blood Transfusion | 1 | 2003 | 73 | 0.050 |
Why?
|
Anti-Arrhythmia Agents | 1 | 2002 | 10 | 0.050 |
Why?
|
Wounds, Nonpenetrating | 1 | 2003 | 88 | 0.050 |
Why?
|
Cardiotonic Agents | 1 | 2002 | 48 | 0.050 |
Why?
|
Pre-Eclampsia | 1 | 2003 | 66 | 0.050 |
Why?
|
Risk Assessment | 4 | 2012 | 1426 | 0.050 |
Why?
|
Incidence | 1 | 2005 | 1199 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2005 | 411 | 0.050 |
Why?
|
Cesarean Section | 1 | 2003 | 112 | 0.050 |
Why?
|
Cause of Death | 1 | 2002 | 236 | 0.050 |
Why?
|
Angiotensins | 1 | 2021 | 42 | 0.050 |
Why?
|
Hypoglycemic Agents | 1 | 2002 | 181 | 0.050 |
Why?
|
Stroke Volume | 2 | 2020 | 348 | 0.050 |
Why?
|
Cohort Studies | 3 | 2013 | 1817 | 0.040 |
Why?
|
Heart Ventricles | 1 | 2020 | 135 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2020 | 322 | 0.040 |
Why?
|
Academic Medical Centers | 2 | 2011 | 158 | 0.040 |
Why?
|
Immunohistochemistry | 1 | 2020 | 538 | 0.040 |
Why?
|
Punctures | 1 | 2017 | 33 | 0.040 |
Why?
|
Recovery of Function | 1 | 2018 | 199 | 0.040 |
Why?
|
Receptors, Angiotensin | 1 | 2017 | 61 | 0.040 |
Why?
|
Patient Discharge | 1 | 2017 | 188 | 0.030 |
Why?
|
Databases, Factual | 1 | 2017 | 355 | 0.030 |
Why?
|
Child | 1 | 2002 | 2438 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2008 | 276 | 0.030 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2015 | 80 | 0.030 |
Why?
|
Up-Regulation | 1 | 2015 | 189 | 0.030 |
Why?
|
Rodentia | 1 | 2014 | 9 | 0.030 |
Why?
|
Aging | 1 | 2021 | 946 | 0.030 |
Why?
|
Adolescent | 1 | 2002 | 3539 | 0.030 |
Why?
|
Substrate Specificity | 1 | 2014 | 87 | 0.030 |
Why?
|
Amino Acid Sequence | 1 | 2014 | 285 | 0.030 |
Why?
|
Chest Tubes | 1 | 2013 | 5 | 0.030 |
Why?
|
Circulatory Arrest, Deep Hypothermia Induced | 1 | 2013 | 4 | 0.030 |
Why?
|
Blood Coagulation Disorders | 1 | 2013 | 13 | 0.030 |
Why?
|
Molecular Sequence Data | 1 | 2014 | 359 | 0.030 |
Why?
|
Heart | 1 | 2014 | 177 | 0.030 |
Why?
|
Sternotomy | 1 | 2012 | 3 | 0.030 |
Why?
|
Recombinant Proteins | 1 | 2013 | 247 | 0.030 |
Why?
|
Rare Diseases | 1 | 2012 | 21 | 0.030 |
Why?
|
Anastomosis, Surgical | 1 | 2012 | 58 | 0.030 |
Why?
|
Radiography | 2 | 2004 | 376 | 0.030 |
Why?
|
Angiography | 1 | 2012 | 80 | 0.030 |
Why?
|
Combined Modality Therapy | 1 | 2012 | 560 | 0.020 |
Why?
|
Critical Care | 1 | 2011 | 106 | 0.020 |
Why?
|
Stress, Mechanical | 1 | 2009 | 92 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2011 | 232 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2011 | 898 | 0.020 |
Why?
|
Sheep | 1 | 2009 | 233 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2010 | 582 | 0.020 |
Why?
|
Blood Volume | 1 | 2008 | 8 | 0.020 |
Why?
|
Platelet Transfusion | 1 | 2008 | 16 | 0.020 |
Why?
|
Rupture, Spontaneous | 1 | 2007 | 20 | 0.020 |
Why?
|
Radiographic Image Enhancement | 1 | 2007 | 26 | 0.020 |
Why?
|
Erythrocyte Transfusion | 1 | 2008 | 35 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2010 | 762 | 0.020 |
Why?
|
Prevalence | 1 | 2010 | 981 | 0.020 |
Why?
|
Treatment Failure | 1 | 2005 | 162 | 0.020 |
Why?
|
History, 17th Century | 1 | 2004 | 2 | 0.020 |
Why?
|
Heart Function Tests | 1 | 2004 | 9 | 0.010 |
Why?
|
Anesthesia, General | 1 | 2004 | 28 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2005 | 525 | 0.010 |
Why?
|
Paraplegia | 1 | 2003 | 7 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2003 | 100 | 0.010 |
Why?
|
Heparin | 1 | 2003 | 73 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2004 | 517 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2003 | 633 | 0.010 |
Why?
|
Coronary Artery Disease | 1 | 2004 | 401 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 2004 | 475 | 0.010 |
Why?
|
Blood Glucose | 1 | 2002 | 494 | 0.010 |
Why?
|
Pregnancy | 1 | 2003 | 997 | 0.010 |
Why?
|